Long-Acting Amylin Analogue

Cagrilintide

Once-Weekly Amylin Receptor Agonist • Investigational Weight-Management Peptide

Cagrilintide is a long-acting amylin analogue studied as a once-weekly treatment for obesity, both alone and with semaglutide as CagriSema. It engages amylin and calcitonin receptors rather than GLP-1, GIP, or glucagon receptors, adding a separate satiety pathway.

Routes

SubQ

Compound type

Peptide

Regulatory status

Not FDA approved

Last reviewed

September 17, 2026

At a glance

Cagrilintide Quick Reference

Starting Dose: Members only
Sign in to view dosing details.
Target Dose: Members only
Sign in to view dosing details.
Route: SubQ
Long-acting formulation studied as a weekly injection.
Evidence: Phase 3
Strongest evidence is for CagriSema, not untested peptide combinations.

Overview

What Is Cagrilintide?

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone released alongside insulin after meals. Amylin contributes to satiety, slows gastric emptying, and helps regulate post-meal glucose.

Natural amylin is short-lived. Cagrilintide was engineered for prolonged activity that supports once-weekly administration. Its receptor pathway is distinct from GLP-1, GIP, and glucagon agonism.

The strongest clinical evidence comes from CagriSema, the fixed-dose combination of cagrilintide and semaglutide. In REDEFINE 1, CagriSema produced a mean 20.4% weight reduction at 68 weeks using the treatment-policy estimand; 60% of participants lost at least 20%, and approximately 23% lost at least 30%.

Cagrilintide also produced dose-dependent standalone weight loss in phase 2 research. The 4.5mg group lost approximately 10.8% over 26 weeks, compared with approximately 9% with daily liraglutide 3mg.

In 2026, REDEFINE 4 found substantial weight loss with CagriSema but did not demonstrate non-inferiority to tirzepatide. This reinforces that CagriSema is effective, while limiting claims that it is categorically superior to other leading obesity therapies.

Peptide ProtocolsGrade

Cagrilintide earns a B for meaningful human weight-loss results and a mechanism that complements GLP-1 therapies. As a long-acting amylin analogue, it acts on appetite and satiety signaling to help reduce food intake, with once-weekly administration adding practical appeal. Clinical trials show weight loss with cagrilintide alone and greater reductions when combined with semaglutide, giving it a stronger foundation than compounds supported only by animal research. Nausea, constipation, and other gastrointestinal effects can limit tolerability, while combination-trial results should not be attributed to cagrilintide alone. Those tradeoffs, together with remaining questions about long-term outcomes and use outside controlled trials, keep it below the top tier.

ResearchCommunitySafety

Mechanism

Cagrilintide Mechanism of Action

Amylin signaling

Long-acting analogue

Natural amylin is short-lived. Cagrilintide was engineered for prolonged activity that supports once-weekly administration. Its receptor pathway is distinct from GLP-1, GIP, and glucagon agonism.

Research findings

Cagrilintide Benefits

The most credible benefits come from randomized trials of cagrilintide alone and CagriSema. Results from semaglutide combinations should not be assumed to apply identically to tirzepatide or retatrutide combinations.

Weight Reduction

Cagrilintide alone and CagriSema have produced clinically meaningful, dose-dependent weight loss in controlled trials.

Distinct Satiety Mechanism

Amylin-receptor activity adds a pathway separate from GLP-1, GIP, and glucagon receptor agonism.

Glycemic Improvement

CagriSema trials in type 2 diabetes reported improvements in HbA1c and body weight.

Once-Weekly Dosing

Its extended activity supports a weekly injection schedule.

Reduced Food Noise

Users and trial participants often describe stronger fullness and reduced persistent hunger.

Standalone Activity

Phase 2 data indicates that cagrilintide has meaningful weight-management activity independent of semaglutide.

Protocol planning

Cagrilintide Dosing Protocol

Members Access Only

Preparation

Cagrilintide Reconstitution

Reconstitution Example

10mg vial + 2mL compatible diluent

Result5mg/mL

Reconstitution steps

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

Storage

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Cagrilintide Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users often describe a distinct physical feeling of fullness rather than only reduced mental cravings.
Some report that large meals or overeating become physically difficult because food feels as though it remains in the stomach longer.
Some users report breaking weight-loss plateaus after adding cagrilintide to an existing protocol.

Negative & Mixed Reports

Moderate-to-severe fatigue is reported during the first few weeks or after dose increases. Some users say it improves with adaptation, although persistent or severe fatigue warrants medical evaluation.
Nausea, excessive fullness, constipation, and reduced ability to eat enough protein are recurring complaints.
Some users find the physical satiety sensation unpleasant or more difficult to manage than GLP-1-related appetite suppression.

Stacking & synergy

Cagrilintide Stacking & Synergy

The evidence base differs sharply by combination. Mechanistic complementarity is not a substitute for controlled safety data.

Cagrilintide + Semaglutide

CagriSema is the researched combination with phase 3 evidence and a manufacturer-tested fixed-dose formulation.

Cagrilintide + Retatrutide

Amylin signaling may complement retatrutide’s GLP-1/GIP/glucagon activity, but the combination has not been tested in controlled trials.

Cagrilintide + Tirzepatide

This pairing is also unstudied and may intensify gastrointestinal and hydration-related adverse effects.

Safety notes

Cagrilintide Side Effects & Safety

Gastrointestinal effects are the most common adverse events and may be more pronounced during escalation or when cagrilintide is combined with another appetite-suppressing therapy.

Controlled safety data are strongest for cagrilintide alone and CagriSema. Comparable safety data do not exist for combinations with tirzepatide or retatrutide.

Common Effects

Nausea, sometimes with vomiting.
Constipation or diarrhea.
Abdominal discomfort and excessive fullness.
Marked appetite reduction and fatigue.

Less Common & Urgent Signs

Headache, dizziness, or injection-site reactions.
Hypoglycemia risk is greatest with insulin or sulfonylureas.
Persistent vomiting, severe dehydration, or severe abdominal pain requires medical evaluation.
Rash, swelling, or difficulty breathing requires emergency care.

Cagrilintide Precautions

Use Caution With

History of pancreatitis.
Gallbladder disease.
Gastroparesis or another gastrointestinal motility disorder.
Kidney disease, especially when vomiting or dehydration occurs.
Type 1 diabetes, which has not been established as an appropriate use population.
Pregnancy and Breastfeeding: Cagrilintide has not been established as safe during pregnancy or breastfeeding. Weight-loss therapy should be avoided during pregnancy.
Regulatory Status: Cagrilintide is not FDA approved as a standalone medication. CagriSema was submitted to the FDA in early 2026 but remains investigational while regulatory review is pending.

Drug Interactions

Insulin and sulfonylureas may require clinician-guided adjustment because of hypoglycemia risk.
Delayed gastric emptying may alter the timing of absorption for oral medications, especially drugs requiring rapid or predictable uptake.

Cagrilintide is not FDA approved.

Final verdict

Peptide Protocols Verdict on Cagrilintide

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

We view Cagrilintide as a powerful appetite and metabolic control agent. When paired with Tirzepatide or Retatrutide, it elevates hunger suppression and fat loss results while often smoothing out some of the typical GLP-1 side effects. Community members consistently note more sustainable weight loss and better adherence.

It shines for those who struggle with constant hunger on single agonists. Smart addition to advanced recomp stacks when appetite is the primary barrier.